Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies for cancers, bacterial diseases, and viral infections. The company develops EVX-01, a cancer immunotherapy that is in clinical Phase IIb trial for metastatic melanoma; EVX-02, a DNA-based cancer immunotherapy that is in Phase IIa trial for adjuvant melanoma; and EVX-03, a DNA-based immunotherapy for the treatment of various cancers. Its programs also include EVX-B1, EVX-B2, and EVX-V1, which are vaccines that are in pre-clinical stage for the treatment of bacterial and viral diseases. The company was incorporated in 2008 and is headquartered in Hørsholm, Denmark.

Evaxion Biotech A/S

We are a clinical-stage AI-immunology™ platform company using our proprietary artificial intelligence, or AI, technology, engineering expertise and drug development know-how to simulate the human immune system and generate predictive models to identify and develop novel immunotherapies for the treatment of various cancers, bacterial diseases and viral infections. 
We are currently in the clinic with our two lead product candidates, EVX-01 and EVX-02, for the treatment of various cancers.

We have four proprietary AI prediction models: PIONEER, ObsERV, EDEN and RAVEN.

Metric
Company Name	Evaxion Biotech A/S
Symbol	EVAX
MSH ID	COM:EVAXION-BIOTECH
Market	STOCKS
Sector	Healthcare
Industry	Biotechnology
Country	DK
Stage	Post-IPO Equity
Employee Count	49
Website	evaxion-biotech.com
LinkedIn	evaxion-biotech
Founders

Metric
Market Cap	16.59M
Enterprise Value
Monthly Web Traffic	1.64K
Web Traffic Growth	-0.20
Valuation
Raised Capital	15M

Metric
Revenue	73.11K
Revenue (LTM)
Revenue (NTM)
Gross Profit	73.11K
EBITDA	-21.62M
Operating Income	-22.23M
Net Income	-22.16M
EPS	-8.11
Diluted EPS	-8.11
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	1
Operating Profit Margin
EBITDA Margin	-295.65
Net Profit Margin
Return on Equity	0.67
Return on Assets	0.33
Return on Capital Employed	0.32

COM:EVAXION-BIOTECH

Evaxion Biotech A/S

Last Close

1.39

22/11 21:00

Market Cap

16.59M

Beta: -

Volume Today

13.33K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.47
P/B Ratio	-0.13
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	295.48
EV Multiple	-0.46

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover	0.02

Metric
Operating Cash Flow	-17.72M
Free Cash Flow	-17.81M
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield	0.15

Metric
Cash & Equivalents	5.58M
Accounts Receivable	1.11M
Inventory
Goodwill
Debt to Capitalization	2.11
Debt to Assets
Current Ratio
Quick Ratio	2.80

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue